The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes

Rockefeller University109 enrolled

Overview

The investigators believe that T cells, cells that are a part of the immune system, are what are causing the neurological problems while also attacking tumor cells. This protocol studies the clinical status of patients with paraneoplastic neurological disorder (PND) as well as their blood to understand the relationship between their neurological disease, their cancer, and their immune system.

Patients with paraneoplastic neurological disorders (PNDs) provide a unique model for studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte autoimmune dysfunction is involved in the pathogenesis of the paraneoplastic neurological syndromes, and that killer T cells are involved in the targeting and successful killing of tumor cells in these cancer patients. Furthermore, we postulate that this activity may provide a model for autoimmune brain disease. We will assess the immune responses in PND patients, correlate these with the clinical data (time course of disease, symptoms and signs, disability), and collect and archive clinical data, serum and cells from PND patients for current and future studies into the basic immune system phenomenon present in PND patients.

Study Type

OBSERVATIONAL

Enrollment

109

Conditions

Paraneoplastic Syndromes

Eligibility

Sex: ALLMin age: 1 Year

Medical Language ↔ Plain English

Inclusion Criteria: * Neurological disease which is suspected to be paraneoplastic * No known active additional malignancy other than non-melanoma skin cancer Exclusion Criteria: * Known central nervous system (CNS) metastasis * Known active additional malignancy * No pulmonary disease which limits daily activities if leukapheresis: must be 14 or older no known hepatitis B or C, HIV, or syphilis (by history or prior negative tests) no known IV drug users HgB \> 8.5 WBC \> 3,500 platelets \> 100,000 INR \< 2 if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known IV drug users HgB \> 10 WBC \> 3,500 platelets \> 100,000 INR \< 2 if lumbar puncture: platelets \> 120,000 INR \< 1.2 must be 14 or older

Locations (1)

Rockefeller University Hospital

New York, New York, United States

Outcomes

Primary Outcomes

Immunologic responses to tumor antigens in vitro

ELISPOT

Time frame: throughout study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.